Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology
20. Dezember 2024 07:12 ET
|
Research and Markets
Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Targeted Protein Degradation Market by Type, by Application, by End-User, and by Region" report has been added to ResearchAndMarkets.com's...
Targeted Protein Degradation Market Research, 2018-2030: Size, Share & Trends Analysis by Type, Application, End-use and Region
11. Dezember 2024 04:21 ET
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation Market Size, Share & Trends Analysis by Type (PROTAC, LYTACs), Application (Drug Discovery), End Use (Hospitals,...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
10. Dezember 2024 09:05 ET
|
Arvinas Inc.
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
09. Dezember 2024 18:00 ET
|
Nurix Therapeutics, Inc.
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments Treatment...
Targeted Protein Degradation Market Growing at 20.7% CAGR to Hit USD 3547.91 million by 2034 | PMR
09. Dezember 2024 06:35 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Market Overview The global targeted protein degradation market size is projected to grow from USD 541.98 million in 2024 to USD 3547.91 million by...
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
27. November 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
26. November 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
26. November 2024 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
25. November 2024 17:35 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
17. November 2024 10:30 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...